drugset / Trial / NCT04898270
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Non-randomizedSingle-groupSingle-blindTreatment
Summary
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients. This study is the first clinical trial to explore the treatment of patients with flupentixol combined with MARTAs. However, due to research limitations, the number of patients who participated in the clinical trial is small, and it depends on subsequent larger-scale clinical trials for more in-depth verification.
Timeline
- Start
- 2019-12-19
- Primary completion
- 2020-12-31
- Completion
- 2021-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flupentixol | Unknown | 5 mg | — |
| Subject | Flupentixol | Unknown | 20 mg | — |
| Background | Clozapine | Other / unclassified | — | — |
| Background | Olanzapine | Small molecule | — | — |
| Background | Quetiapine | Small molecule | — | — |